Latest Breaking News On - Caroline hastings - Page 4 : comparemela.com

Cyclo Therapeutics (CYTH) Reports Publication of Data from Phase 2 Study of Trappsol Cyclo

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

– Data published in official journal of Molecular Genetics and Metabolism Reports: Evidence of a change in cholesterol homeostasis in peripheral organs and the brain after the initial infusion Trappsol® Cyclo™ was detected in the CSF Completers had an 88.9% improvement in at least two domains of the 17-Domain Niemann-Pick Type C1 Clinical Severity Scale (17D-NPC-CSS) Improvement in Scale Assessment and Rating of Ataxia (SARA) score for the mean score in 7 of 8 domains at Week 48 compared with baseline Demonstrated a favorable benefit-risk profile

Kansas DCF named to National Child Welfare Workforce Institute Collaborative – Newstalk KZRG

TOPEKA  – The Kansas Department for Children and Families (DCF) recently joined the National Child Welfare Workforce Institute’s Breakthrough Series Collaborati

Cyclo Therapeutics (CYTH) Provides Clinical Program Update and Highlights Recent Achievements

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol Cyclo for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

18.10.2022 - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, . Seite 1